Diabetes mellitus in patients with Alzheimer's disease: Clinical description and correlation with the apoe genotype in a sample population from the province of Antioquia, Colombia

Biomedica

Volumn 32, Issue 2, 2012, Pages 239-251

  Botero, Luz E ^a   Toro, Andrés E ^a   Patiño, Alber J ^a   Salazar, Guillermo ^a   Rodríguez, Juan C ^a   Suárez Escudero, Juan C ^a,b   Alarcán, Gustavo A ^a   Corcimaru, Ana ^a,c   Osorio, Cristina ^a,c   Jeong, Joseph S Y ^a,c   Alzate, Oscar ^a,c  

^a UNIVERSIDAD PONTIFICIA BOLIVARIANA   (Colombia)

^b Fundación Instituto Neurológico de Colombia INDEC Medellín   (Colombia)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer,s disease, diabetes mellitus, apolipoprotein E, dementia; pulmonary disease,chronic obstructive.

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLOMBIA; COMORBIDITY; DIABETES MELLITUS; EPILEPSY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HEAD INJURY; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; MALE; NEUROPSYCHOLOGICAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; COLOMBIA; COMORBIDITY; CRANIOCEREBRAL TRAUMA; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; EPILEPSY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; HYPOTHYROIDISM; MALE; MYOCARDIAL INFARCTION; NEUROPSYCHOLOGICAL TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK;

EID: 84869776924     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10:819-28.
2. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement.2010;6:98-103.
3. WHO. Atlas: Country resources for neurological disorders.World Health Organization and World Federation of Neurology. Geneva: WHO; 2004. p. 52.
4. Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev. 2001;81:741-66.
5. Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med. 1999;340:1970-80.
6. Huang C, Wahlund LO, Svensson L, Winblad B, Julin P.Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurol. 2002; 2:9.
7. Dede DS, Yavuz B, Yavuz BB, Cankurtaran M, Halil M, Ulger Z, et al. Assessment of endothelial function in Alzheimer's disease: Is Alzheimer's disease a vascular disease? J Am Geriatr Soc. 2007;55:1613-7.
8. Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, et al. Gene delivery of human apolipoprotein E alters brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A.2005;102:1211-6.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition.Washington, DC: APA; 2000. p. 157.
10. Dickson DW. Neuropathological diagnosis of Alzheimer'sdisease: A perspective from longitudinal clinicopathological studies. Neurobiol Aging. 1997;18(Suppl.):S21-6.
11. Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med. 2010;4:51-63.
12. Alzheimer's Association, Thies W, Bleiler L. Alzheimer's disease facts and figures. Alzheimers Dement. 2011;7:208-44.
13. Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Helkala EL, Hartikainen P, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: Relation to apolipoprotein E polymorphism. Neurology. 1996;46:413-9.
14. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama Study. Neurology.1995;45:1161-8.
15. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvensen GS, et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977-81.
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care.2009;32(Suppl.1):S62-7.
17. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.Diabetes Res Clin Pract. 2002;55:65-85.
18. Ryden L, Standl E, Bartnik M, van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88-136.
19. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40.
20. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome aspredictors of incident cardiovascular disease and diabetes.Diabetes Care. 2007;30:8-13.
21. WHO. Diabetes. Geneve: WHO; 2011. Accessed: September 15, 2011. Disponible en: http://www.who.int/mediacentre/factsheets/fs312/en/index.html
22. Aschner P. Diabetes trends in Latin America. Diabetes Metab Res Rev. 2002;18(Suppl.3):S27-31.
23. Alzheimer's Disease Association. Standards of medical care in diabetes -2011. Diabetes Care. 2011;34(Suppl.1):S11-61.
24. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, et al. Glucose tolerance status and risk of dementia in the community: The Hisayama Study. Neurology. 2011; 77:1126-34.
25. Peila R, Rodríguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002;51:1256-62.
26. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hänninen T, et al. Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension. 1993;22:771-9.
27. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, et al. Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemiol. 1997;145:301-8.
28. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53:1937-42.
29. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry. 2006;11:721-36.
30. Messier C. Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp Gerontol. 2003;38:941-6.
31. Mahley RW, Huang Y. Apolipoprotein (apo) E4 and Alzheimer s disease: Unique conformational and biophysical properties of apoE4 can modulate neuropathology. Acta Neurol Scand Suppl. 2006;185:8-14.
32. Mahley RW, Huang Y, Weisgraber KH. Putting cholesterol in its place: apoE and reverse cholesterol transport. J Clin Invest. 2006;116:1226-9.
33. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5644-51.
34. Powell DS, Maksoud H, Charge SB, Moffitt JH, Desai M, Da Silva Fihlo RL, et al. Apolipoprotein E genotype, islet amyloid deposition and severity of type 2 diabetes. Diabetes Res Clin Pract. 2003;60:105-10.
35. Edland SD. Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease. J Mol Neurosci. 2004;23:213-7.
36. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-3.
37. Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease. Biol Psychiatry. 1999;45:422-5.
38. Forero DA, Pinzón J, Arboleda GH, Yunis JJ, Álvarez C, Cataño N, et al. Analysis of common polymorphisms in angiotensin-converting enzyme and apolipoprotein Egenes and human longevity in Colombia. Arch Med Res. 2006;37:890-4.
39. Callas N, Poveda E, Baracaldo C, Hernández P, Castillo C, Guerra M. Polimorfismo genético de la apolipoproteína E en un grupo de escolares del centro-oriente colombiano: comparación con las concentraciones plasmáticas de lípidos y apolipoproteínas. Biomédica. 2007;27:526-36.
40. Hernández-Fonseca JP, Rincón J, Pedreanez A, Viera N, Arcaya JL, Carrizo E, et al. Structural and ultrastructural analysis of cerebral cortex, cerebellum, andhypothalamus from diabetic rats. Exp Diabetes Res. 2009;2009:329632.
41. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol. 1998;153:1149-55.
42. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223-34.
43. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, et al. Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A. 1994;91:7787-91.
44. Klein JP, Waxman SG. The brain in diabetes: Molecular changes in neurons and their implications for end-organ damage. Lancet Neurol. 2003;2:548-54.
45. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137-47.
46. Nitsch RM. From acetylcholine to amyloid: Neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration. 1996;5:477-82.
47. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch Neurol. 2009;66:300-5.
48. Kameyama M, Fushimi H, Udaka F. Diabetes mellitus and cerebral vascular disease. Diabetes Res Clin Pract. 1994;24(Suppl.):S205-8.
49. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol. 2006;5:64-74.
50. Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in type II diabetes: Insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans. 2005;33:1041-4.
51. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329-44.
52. Craft S, Watson GS. Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurol. 2004;3:169-78.
53. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 1995;18:172-6.
54. Irie F, Fitzpatrick AL, López OL, Kuller LH, Peila R, Newman AB, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: The Cardiovascular Health Study Cognition Study. Arch Neurol. 2008;65:89-93.
55. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
56. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545-8.
57. Panza F, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, Santamato A, et al. Metabolic syndrome and cognitive impairment: Current epidemiology and possible underlying mechanisms. J Alzheimers Dis. 2011;21:691-724.
58. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Santamato A, et al. Alzheimer's disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet Neurol. 2008;7:812-26.
59. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Arch Neurol. 2003;60:223-8.
60. Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: A community-based, longitudinal study. Stroke. 2003;34:594-9.
61. Strachan MW, Reynolds RM, Marioni RE, Price JF. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol. 2011;7:108-14.
62. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome Vs. Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644-50.
63. Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: Secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Arch Neurol. 2011;68:1245-51.
64. Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: The Rotterdam Study. Lancet. 1998;351:1840-3.
65. Peters R, Poulter R, Warner J, Beckett N, Burch L, Bulpitt C. Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr. 2008;8:36.
66. Reitz C, den Heijer T, van Duijn C, Hofman A, Breteler MM. Relation between smoking and risk of dementia and Alzheimer disease: The Rotterdam Study. Neurology. 2007;69:998-1005.
67. Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: A meta-analysis of prospective studies. Am J Epidemiol. 2007;166:367-78.
68. Debanne SM, Rowland DY, Riedel TM, Cleves MA. Association of Alzheimer's disease and smoking: The case for sibling controls. J Am Geriatr Soc. 2000;48:800-6.
69. Doll R, Peto R, Boreham J, Sutherland I. Smoking and dementia in male British doctors: Prospective study. BMJ. 2000;320:1097-102._rfseq
70. Hill JW, Futterman R, Duttagupta S, Mastey V, Lloyd JR, Fillit H. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. 2002;58:62-70.